Show Summary Details
Page of

Managing hereditary gynaecological cancers 

Managing hereditary gynaecological cancers
Managing hereditary gynaecological cancers

Charlotte Moss

, Emma Crosbie

, and Ana Montes

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 12 July 2020

As oncologists treating gynaecological malignancies we frequently encounter patients with proven or suspected hereditary predisposition to cancer development. Some of these cancers have a different behaviour to sporadic cancers in their epidemiology and prognosis. Knowledge of these patterns of disease enables us to monitor and counsel patients adequately. More importantly, discovery of the faulty pathways associated with hereditary cancers can be exploited therapeutically and there is an important role for new agents alone or in combination with conventional cytotoxic chemotherapy. This chapter reviews the current surgical and medical management of patients with proven hereditary gynaecological malignancies, focusing on BRCA-related ovarian cancer and Lynch Syndrome-related ovarian and endometrial cancer.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.